Combating antimicrobial resistance in malaria, HIV and tuberculosis
- 15 May 2024
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 23 (6) , 461-479
Abstract
Antimicrobial resistance poses a significant threat to the sustainability of effective treatments against the three most prevalent infectious diseases: malaria, human immunodeficiency virus (HIV) infection and tuberculosis. Therefore, there is an urgent need to develop novel drugs and treatment protocols capable of reducing the emergence of resistance and combating it when it does occur. In this Review, we present an overview of the status and underlying molecular mechanisms of drug resistance in these three diseases. We also discuss current strategies to address resistance during the research and development of next-generation therapies. These strategies vary depending on the infectious agent and the array of resistance mechanisms involved. Furthermore, we explore the potential for cross-fertilization of knowledge and technology among these diseases to create innovative approaches for minimizing drug resistance and advancing the discovery and development of new anti-infective treatments. In conclusion, we advocate for the implementation of well-defined strategies to effectively mitigate and manage resistance in all interventions against infectious diseases.Keywords
This publication has 204 references indexed in Scilit:
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in AdultsJAMA, 2023
- Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosisCell, 2021
- Cone-shaped HIV-1 capsids are transported through intact nuclear poresCell, 2021
- HIV‐1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimatesJournal of the International AIDS Society, 2020
- Computer-aided discovery of anti-HIV agentsBioorganic & Medicinal Chemistry, 2016
- Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 LevelsCell Reports, 2016
- Substrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug ResistanceChemistry & Biology, 2013
- Opportunities and Challenges for HIV Care in Overlapping HIV and TB EpidemicsJAMA, 2008
- Risk of Tuberculosis From Exposure to Tobacco SmokeArchives of internal medicine (1960), 2007
- Pyrimethamine resistant mutations in Plasmodium falciparumMolecular and Biochemical Parasitology, 1992